Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.68 |
| ▸ | HTT | P42858 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 1/20 | 0.62 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1256251 | 0.87 | L3MBTL1 (0.54) | SMN1; SMN2KDM4EHTTMEN1KMT2A | |
| SCHEMBL1256363 | 0.85 | NPC1 (0.58) | SMN1; SMN2KDM4EHTTMEN1KMT2A | |
| SCHEMBL1256204 | 0.84 | ADORA2A (0.61) | SMN1; SMN2KDM4EHTTMEN1KMT2A | |
| SCHEMBL1255351 | 0.84 | L3MBTL1 (0.54) | SMN1; SMN2KDM4EMEN1KMT2AADORA2A | |
| SCHEMBL1256952 | 0.84 | ADORA2A (0.62) | ADORA2AADORA1L3MBTL1USP2 | |
| SCHEMBL1254093 | 0.82 | ADORA1 (0.63) | SMN1; SMN2KDM4EADORA2AADORA1MAPT | |
| SCHEMBL1256572 | 0.82 | L3MBTL1 (0.53) | SMN1; SMN2KDM4EHTTMEN1KMT2A | |
| SCHEMBL1256100 | 0.82 | L3MBTL1 (0.53) | SMN1; SMN2KDM4EHTTMEN1KMT2A | |
| SCHEMBL1256333 | 0.82 | L3MBTL1 (0.53) | SMN1; SMN2KDM4EHTTMEN1KMT2A | |
| SCHEMBL1255635 | 0.82 | ADORA2A (0.55) | SMN1; SMN2KDM4EHTTKMT2AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3002283-B1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-06-14 | — | — | EP | disclosed |
| EP-3002283-A1 | THIAZOLE DERIVATIVES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-1700856-B1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-8889718-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20130267509-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8420827-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20110105486-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7880013-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1700856-A1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267509-A1 | THIAZOLE DERIVATIVES | THRA, CHD8, CYP2C8 | SMN1; SMN2 891/4885KDM4E 4495/4885HTT 177/4885 |
| US-20110105486-A1 | THIAZOLE DERIVATIVES | CHD8, CYP2C8, THRA | SMN1; SMN2 4627/4885KDM4E 4497/4885HTT 1199/4885 |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 4865/4885KDM4E 4728/4885HTT 2795/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 848/4885KDM4E 4715/4885HTT 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.